# A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC

> **NCT04108247** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 39 (actual)

## Conditions studied

- Prostate Cancer Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Abiraterone+SHR3162

## Key facts

- **NCT ID:** NCT04108247
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-26
- **Primary completion:** 2023-06
- **Final completion:** 2023-06
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2022-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04108247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04108247, "A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04108247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*